share_log

Senseonics Holdings, Inc. (SENS) Q3 2024 Earnings Call Transcript Summary

Senseonics Holdings, Inc. (SENS) Q3 2024 Earnings Call Transcript Summary

Senseonics Holdings, Inc.(SENS)2024年第三季度業績會議通話摘要
富途資訊 ·  07:37  · 電話會議

The following is a summary of the Senseonics Holdings, Inc. (SENS) Q3 2024 Earnings Call Transcript:

以下是Senseonics Holdings, Inc.(SENS)2024年第三季度業績會議呼叫成績單總結:

Financial Performance:

財務表現:

  • Q3 2024 net revenue was $4.3 million, a decrease from $6.1 million in the previous year, primarily due to inventory adjustments for the Eversense 365 launch.

  • Gross loss for Q3 2024 was $4.1 million, down from a gross profit of $1.2 million year-over-year, influenced by one-time charges linked to the new product transition.

  • Operating loss for the nine months ending September 2024 increased to $22.8 million from $19 million, with a third-quarter net loss of $24 million.

  • 2024年第三季度淨營業收入爲$430萬,較去年$610萬有所下降,主要是由於Eversense 365推出時的庫存調整。

  • 2024年第三季度毛利潤虧損爲$410萬,較去年同期$120萬的毛利潤下降,主要是由於與新產品過渡相關的一次性費用影響。

  • 2024年9月底九個月的營業虧損從$1900萬增加到$2280萬,第三季度淨虧損爲$2400萬。

Business Progress:

業務進展:

  • FDA approval of Eversense 365, a one-year continuous glucose monitor, significantly builds on product advancement.

  • Launch of Eversense 365 with early positive feedback and strong healthcare provider adoption.

  • Strategic moves including acquisition of Eversense Insertion Network assets and plans for cost reductions in 2025 to enhance financial stability.

  • Progress on the development of next-generation sensors, Gemini and Freedom, which offer battery power and direct phone communication respectively.

  • FDA批准Eversense 365,一款爲期一年的持續血糖監測儀,極大地推動了產品進展。

  • Eversense 365推出時得到了積極的初步反饋和醫療保健提供者的積極採納。

  • 戰略舉措包括收購Eversense插入網絡資產和計劃於2025年進行成本削減,以增強財務穩定性。

  • 下一代傳感器Gemini和Freedom的開發進展順利,分別提供電池供電和直接電話通信。

Opportunities:

機會:

  • Eversense 365 coverage by nearly all U.S. insurers and Medicare, enhancing accessibility.

  • Expanded partnerships with health systems, such as Mercy, expected to improve patient outcomes and reduce care costs.

  • Anticipated revenue growth from Eversense 365 in 2025 with improved unit economics.

  • Eversense 365已覆蓋幾乎所有美國保險公司和醫療保險,提高了可及性。

  • 與諸如Mercy等衛生系統的合作伙伴關係擴大,預計將改善患者結果並降低護理成本。

  • 預計Eversense 365將於2025年實現營業收入增長,並改善單位經濟學。

Risks:

風險:

  • Transitioning to Eversense 365 impacts short-term revenue due to inventory management and product switchovers, particularly affecting Q3 and possibly extending into early 2025.

  • 轉向Eversense 365影響短期營業收入,由於庫存管理和產品切換,特別影響第三季度,可能延伸至2025年初。

Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.

提示:如需更全面的詳情,請參閱投資人關係網站。本文僅供投資者參考,不作任何指引或建議。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論